Original Publication Date: 1 September, 2014
Publication / Source: Breast Cancer Management
Authors: Gizeh Pérez-Tenorio, Elin Karlsson, Olle Stål
Overactivation of the PI3K/AKT signaling pathway is frequently reported in breast cancer, consequently inhibitors targeting this pathway are clinically useful. AKT constitutes a hub in the regulation of several cancer hallmarks, such as proliferation, survival and migration. Three AKT isoforms, named AKT1, AKT2 and AKT3, are identified in humans.